Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ABBOTT LABORATORIES
Bear Case (25th pct.)
-45.4% vs price
Base Case (Median)
-34.9% vs price
Bull Case (75th pct.)
-23.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $85.93 | -16.2% | High (40%) |
| PE Comparable | $70.24 | -31.5% | Medium (25%) |
| Growth Trajectory DCF | $66.75 | -34.9% | Medium (20%) |
| Graham Number | $45.63 | -55.5% | Medium (40%) |
| EV/EBITDA | $63.15 | -38.4% | Medium (20%) |
| EV/FCF | $86.68 | -15.5% | Medium (20%) |
| Earnings Power Value | $48.82 | -52.4% | Medium (50%) |
Based on 7 out of 7 methods, ABT appears overvalued at the current price of $102.56. The base case fair value of $66.75 implies 34.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.